Radcliffe Capital Management’s Starling Oncology STLN Stock Holding History

Radcliffe Capital Management’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-349,900	Closed	-$3.48M	–	1067
2021 Q3	$3.48M	Hold	349,900	–	–	0.1%	296
2021 Q2	$3.48M	Hold	349,900	–	–	0.11%	309
2021 Q1	$3.48M	Hold	349,900	–	–	0.14%	275
2020 Q4	$3.78M	Buy	349,900 +99,900	+40%	+$1.03M	0.24%	135
2020 Q3	$2.6M	Hold	250,000	–	–	0.23%	99
2020 Q2	$2.51M	Buy	+250,000	New	+$2.49M	0.34%	57

Other funds holding STLN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

PGM

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Radcliffe Capital Management's STLN Position: Q4 2021 in Review

Radcliffe Capital Management sold out of Starling Oncology (STLN) in Q4 2021, closing a stake of 349,900 shares — an estimated $3.48M sold.

Radcliffe Capital Management first reported a position in STLN in Q2 2020 and held it in 6 quarters. The position peaked at $3.78M in Q4 2020. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

Radcliffe Capital Management reported no remaining Starling Oncology position as of Q4 2021 after selling out during the quarter.
Radcliffe Capital Management sold 349,900 Starling Oncology shares in Q4 2021, an estimated $3.48M.
Radcliffe Capital Management first reported a position in Starling Oncology in Q2 2020 and held it in 6 quarters.
Radcliffe Capital Management's Starling Oncology position peaked at $3.78M in Q4 2020.
21 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2021.

Based on Radcliffe Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.